Novartis has entered an agreement to acquire The Medicines Company, a U.S.-based biopharmaceutical company, for 9.7 billion. The deal bolsters Novartis’ cardiovascular drug portfolio with the addition of inclisiran.   The Medicines Company recently unveiled data from its comprehensive clinical program consisting of three Phase III trials (ORION-9, 10 and 11) for inclisiran involving over 3,600 high-risk patients with ASCVD and FH. In all trials, inclisiran demonstrated potent and durable LDL-C r...